ketorolac has been researched along with Endometrial Neoplasms in 2 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compare postoperative pain scores following hysterectomy in patients receiving perioperative celecoxib versus postoperative ketorolac as part of a multimodal pain regimen." | 2.87 | Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial. ( ElNaggar, AC; Tillmanns, TD; Ulm, MA, 2018) |
| "The indication for surgery was: endometrial cancer (n=82; 41%), ovarian cancer (n=5; 2." | 1.40 | The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. ( Barakat, RR; Calderon, B; Gardner, GJ; Lee, SJ; Leitao, MM; Mays, A; Nolan, S; Sonoda, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ulm, MA | 1 |
| ElNaggar, AC | 1 |
| Tillmanns, TD | 1 |
| Lee, SJ | 1 |
| Calderon, B | 1 |
| Gardner, GJ | 1 |
| Mays, A | 1 |
| Nolan, S | 1 |
| Sonoda, Y | 1 |
| Barakat, RR | 1 |
| Leitao, MM | 1 |
1 trial available for ketorolac and Endometrial Neoplasms
| Article | Year |
|---|---|
Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adult; Aged; Analgesi | 2018 |
1 other study available for ketorolac and Endometrial Neoplasms
| Article | Year |
|---|---|
The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies | 2014 |